Abstract:Retinoid X receptor alpha (RXRα) and its N-terminally truncated version, tRXRα, are widely implicated in cancer development and represent intriguing targets for cancer prevention and treatment. Successful manipulation of RXRα and tRXRα requires the identification of their modulators that could produce therapeutic effects. Here, we report that a class of nitrostyrene derivatives bind to RXRα by a unique mechanism, of which the nitro group of nitrostyrene derivatives and Cys432 of RXRα are required for binding. The binding results in the potent activation of Gal4-DBD-RXRα-LBD transactivation. However, the binding inhibits the transactivation of RXRα homodimer, which might be due to the distinct conformation of RXRα homodimer induced by these nitrostyrene derivatives. Two RXRα point mutants with Cys432 substituted with Tyr and Trp, respectively, could mimic the bindings of two nitrostyrene derivatives and have the ability of autotransactivation. In studying the functional consequences of the binding, we show that these nitrostyrene derivatives could potently inhibit the TNFα/NFκB signaling pathway in a tRXRα-dependent manner. tRXRα promotes TNFα-induced NF-κB activation through its interaction with TRAF2 and enhances TNFα-induced ubiquitination of RIP1, which is strongly inhibited by nitrostyrene derivatives. The inhibition of TNFα-induced NF-κB activation results in the synergistic effect of the combination of nitrostyrene derivatives and TNFα on the induction of cancer cell apoptosis. Together, our results show a new class of RXRα modulators that induce apoptosis of cancer cells through their unique binding mode and new mechanism of action.

Synthesis and SAR Study of Modulators Inhibiting Trxrα-Dependent AKT Activation.

Sulindac-derived RXRα Modulators Inhibit Cancer Cell Growth by Binding to a Novel Site.

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Design, Synthesis and Biological Evaluation of Tetrazole-Containing RXRα Ligands As Anticancer Agents.

NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Structure-based Discovery of New Modulators Targeting Nuclear X Receptor Alpha for Cancer Therapy

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

Binding Characterization, Synthesis and Biological Evaluation of RXRα Antagonists Targeting the Coactivator Binding Site

Design and SAR of Withangulatin A Analogues That Act As Covalent TrxR Inhibitors Through the Michael Addition Reaction Showing Potential in Cancer Treatment.

Synthesis and Molecular Recognition Studies on Small-Molecule Inhibitors for Thioredoxin Reductase

Regulation of the Nongenomic Actions of Retinoid X Receptor-Α by Targeting the Coregulator-Binding Sites

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Synthesis and Biological Evaluation of (3/4-(Pyrimidin-2-ylamino)benzoyl)-based Hydrazine-1-carboxamide/carbothioamide Derivatives As Novel RXRα Antagonists.

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα

Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.

Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents

Retinoid X Receptor-Α (RXRA; RXRα)

Overview of the Structure-Based Non-Genomic Effects of the Nuclear Receptor RXRα